Acute Lymphoblastic Leukemia in Elderly Patients: A Single Institution's Experience.
10.3904/kjim.2011.26.3.328
- Author:
Dong Yeop SHIN
1
;
Inho KIM
;
Ki Hwan KIM
;
Younak CHOI
;
Seung Hoon BEOM
;
Yaewon YANG
;
Yoojoo LIM
;
Eunyoung LEE
;
June Koo LEE
;
Ji Yeon KIM
;
Hyun Kyung KIM
;
Sung Soo YOON
;
Dong Soon LEE
;
Seonyang PARK
;
Byoung Kook KIM
Author Information
1. Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea. kim_dajung@hanmail.net
- Publication Type:Original Article ; Comparative Study ; Research Support, Non-U.S. Gov't
- Keywords:
Leukemia, lymphoid;
Aged;
Prognosis;
Philadelphia chromosome
- MeSH:
Adolescent;
Adult;
Age Factors;
Aged;
Aged, 80 and over;
Bone Marrow Examination;
Chi-Square Distribution;
Disease-Free Survival;
Female;
Humans;
Kaplan-Meier Estimate;
Logistic Models;
Male;
Middle Aged;
Philadelphia Chromosome;
*Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis/drug therapy/genetics/immunology/mortality;
Proportional Hazards Models;
Remission Induction;
Republic of Korea;
Retrospective Studies;
Risk Assessment;
Risk Factors;
Survival Rate;
Time Factors;
Treatment Outcome;
Young Adult
- From:The Korean Journal of Internal Medicine
2011;26(3):328-339
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: We investigated the clinical characteristics and prognosis of elderly patients with acute lymphoblastic leukemia (ALL). METHODS: We reviewed the clinical data, laboratory findings, bone marrow findings, and cytogenetic analysis of elderly patients (> or = 60 years) with ALL, and data of an additional 101 younger adult patients (< 60 years) with ALL were reviewed for comparison. RESULTS: Twenty-six elderly patients (> or = 60 years) and 101 younger adult patients (< 60 years) with ALL were retrospectively enrolled. The median follow-up duration was 6.0 months (range, 0.4 to 113.2) in the elderly patients and 21.7 months (range, 1.0 to 122.7) in the adult patients. In total, 34.6% (9 patients) of the elderly patients and 24.8% (25 patients) of the adult patients had Philadelphia chromosome positive ALL. The overall complete remission (CR) rate was much higher in the younger than in the elderly patients (94.1% vs. 57.7%, p < 0.001). The median overall survival (OS) of the younger patients (< 60 years) was 26.3 months, whereas that of the elderly patients (> or = 60 years) was 10.3 months (p = 0.003). In the elderly patients with ALL, T cell lineage and the presence of lymphadenopathy were significant prognostic factors for OS in a univariate analysis (p = 0.033 and 0.041, respectively). CONCLUSIONS: The outcomes of Korean elderly patients with ALL were poor, and the shorter OS was mainly due to the low CR rate. T-cell lineage and the presence of lymphadenopathy were significant prognostic factors in Korean elderly patients with ALL.
